News Article
Flexible Funding Model – Infrastructure, Development, and Maintenance for State Manufactured Food Regulatory Programs (U18) Cooperative Agreement Program
Posted on November 09, 2017
Blog:
The U.S. food and Drug Administration, Office of Partnerships (OP) announced the posting of the Conformance with Flexible Funding Model – Infrastructure, Development, and Maintenance for State Manufactured Food Regulatory Programs (U18) Cooperative Agreement Program. Awards up to $640,000 per year will be given, based upon funding levels and options selected. Programs may receive up to 5 years of funding, based on performance and availability of funds.
If you are interested in applying for this cooperative agreement, you are strongly encouraged to submit a letter of intent by November 22, 2017 in order to participate in the technical review session. The first application due date is March 1, 2018.
The intended outcome of this FOA is to advance efforts for a nationally integrated food safety system (IFSS) by supporting Manufactured Food Regulatory Program Standards (MFRPS), Rapid Response Teams (RRT), Food Protection Task Force (FPTF) programs, and special projects.
For additional information, please visit: https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-18-001.html
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows FDA staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
- Descriptive title of proposed activity
- Name(s), email address(es), and telephone number(s) of the PD(s)/PI(s)
- Names of other key personnel
- Participating institution(s)
- Number and title of this funding opportunity
The letter of intent should be sent via electronic mail as a PDF file with the FOA Number and the Institution's Name in the message subject heading to:
Email: Daniel.Lukash@fda.hhs.gov